Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$1.21 CAD
Change Today -0.02 / -1.63%
Volume 13.0K
As of 3:56 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

bioasis technologies inc (BTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - C$1.50
52 Week Low
08/24/15 - C$0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bioasis technologies inc (BTI) Related Businessweek News

No Related Businessweek News Found

bioasis technologies inc (BTI) Details

biOasis Technologies Inc. operates as a development stage biopharmaceutical company. The company researches, develops, and commercializes technologies and products for the treatment of central nervous system and brain diseases. It develops Transcend and Transcendpep platforms for the transport of therapeutic agents across the blood brain barrier to treat brain cancers, neurodegenerative and metabolic diseases, and small-interfering RNA gene therapy. The company has a research and evaluation agreement with Medimmune Limited; and a research collaboration agreement with Brigham and Women’s Hospital Inc. biOasis Technologies Inc. was incorporated in 2006 and is headquartered in Richmond, Canada.

Founded in 2006

bioasis technologies inc (BTI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: C$166.0K
Compensation as of Fiscal Year 2014.

bioasis technologies inc (BTI) Key Developments

biOasis Technologies Inc. and Brigham and Women's Hospital Enter Research Collaboration Agreement

biOasis Technologies Inc. announced that it is entered into a Research Collaboration Agreement with Brigham and Women’s Hospital Inc. Using biOasis’s Transcend Platform peptide carrier, MTfp, biOasis and researchers lead by Dr. Sean Lawler from the Department of Neurosurgery, Harvard Medical School, will work to deliver a number of compounds targeting glioblastoma tumors within the brain. The initial focus of the collaboration will be on the compounds, MTfp-TZM, MTfp-siRNA and MTfp-miRNA. The work will include moving the trastuzumab program forward towards human clinical trials.

biOasis Technologies Inc. Auditor Raises 'Going Concern' Doubt

biOasis Technologies Inc. filed its Annual on Jun 29, 2015 for the period ending Feb 28, 2015. In this report its auditor, Manning Elliott, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

biOasis Announces Collaboration with the National Research Council of Canada and the Universite de Sherbrooke in Research Project

biOasis announced that it is collaborating with the National Research Council of Canada and the Universite de Sherbrooke in a research project entitled "Focus on Brain," where the partners will identify a new generation of potential blood-brain barrier (BBB) carrier molecules. The overall project goal is to transfer new brain delivery technology to biOasis for commercial development through licensing agreements with major pharmaceutical companies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTI:CN C$1.21 CAD -0.02

BTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTI.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 30.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOASIS TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at